GSK Coreg Post-MI Survival Backed By Beta Blocker Experience – FDA Cmte.
Executive Summary
GlaxoSmithKline's Coreg use in the reduction of post-myocardial infarction mortality is supported by previous experience with other beta blockers in that setting, FDA's cardiovascular advisory committee said
You may also be interested in...
GSK Coreg Labeling Cites 23% Mortality Risk Reduction In Post-MI Indication
GlaxoSmithKline's Coreg labeling states that data show a mortality risk reduction of 23% in patients taking the drug after suffering a myocardial infarction
GSK Coreg Labeling Cites 23% Mortality Risk Reduction In Post-MI Indication
GlaxoSmithKline's Coreg labeling states that data show a mortality risk reduction of 23% in patients taking the drug after suffering a myocardial infarction
Merck Cozaar, Bristol Avapro Gain Nephropathy Indication On Shared Data
FDA approvals of Merck's Cozaar (losartan) and Bristol/Sanofi's Avapro (irbesartan) for the treatment of nephropathy in type 2 diabetes patients are based on data shared by the companies under a reciprocal agreement